Press Releases
March 12, 2008
Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial
February 7, 2008
Avicena Group to Present at 10Th Annual BioCEO & Investor Conference
December 3, 2007
Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
November 19, 2007
Data on Avicena's Drug Candidate HD-02 Presented at the 2007 World Congress on Huntington's Disease
November 13, 2007
USPTO Issues Patent for Avicena Group's Proprietary Compounds to Treat Amyotrophic Lateral Sclerosis
November 1, 2007
Avicena to Present at 9th Annual Acumen BioFin Healthcare Conference
October 23, 2007
Avicena Announces the Commercial Launch of its Nurigene™ Anti-Aging Skin Care Regimen
October 18, 2007
Survival Data for Avicena's Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
October 10, 2007
Avicena Appoints Dr. Belinda Tsao-Nivaggioli as Chairman of the Board of Directors
October 08, 2007
Avicena to Present at 9th Annual Acumen BioFin Healthcare Conference
September 28, 2007
Avicena Appoints Dr. M. Flint Beal to Board of Directors
September 26, 2007
Avicena Group Announces Closing of Private Offering
August 30, 2007
Avicena Reports Second Quarter 2007 Results
August 28, 2007
Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
August 24, 2007
Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
August 17, 2007
Avicena Group to Present at Noble Financial Conference
July 18, 2007
Avicena to be Featured on the Nationally Syndicated Television Series, Heartbeat of America, on July 20, 2007
July 17, 2007
Avicena to Proceed to Confirmatory Phase III Amyotrophic Lateral Sclerosis (ALS) Trial
July 16, 2007
Patient Enrollment on Target in National Institutes of Health Phase III Parkinson's Disease Trial
July 12, 2007
Avicena Engages Rothschild and Bionest As Strategic Advisors
June 28, 2007
Avicena to Advance Huntington's Disease Clinical Program into Phase III
June 12, 2007
Avicena's Proprietary Dermaceutical Compound to be Subject of Presentation at the Strategic Research Institute's 4th Annual Cosmeceuticals Conference
May 24, 2007
Avicena to Present at RedChip Small-Cap Conference
May 21, 2007
Avicena Reports First Quarter 2007 Results
May 14, 2007
Avicena Initiates Phase I Clinical Trial in Amyotrophic Lateral Sclerosis (ALS)
May 11, 2007
Avicena Reports Full Year 2006 Results
May 10, 2007
Avicena to Present at the Rodman & Renshaw Fourth Annual Global Healthcare Conference
May 8, 2007
Avicena and University of Cincinnati Announce Defective Creatine Transporter Gene Present in Autistic Patients
April 26, 2007
Avicena Files Composition of Matter Patent Application for Treatment of Parkinson's Disease
April 24, 2007
Avicena's Huntington's Disease Drug Candidate Selected as One of 100 Great Investigational Drugs of 2007 by R&D Directions
April 23, 2007
Avicena Files Composition of Matter Patent Application for Treatment of Huntington's Disease
March 23, 2007
Avicena Clarifies Description of Creatine Versus PD-02, Company's Lead Drug Compound Used in NIH Phase III Clinical Trial in Parkinson's Disease
March 23, 2007
Avicena to Discuss National Institutes of Health (NIH) Phase III Parkinson's Disease Trial
March 22, 2007
Avicena Announces Patient Enrollment in National Institutes of Health (NIH) Phase III Parkinson's Disease Trial
March 07, 2007
Avicena Receives Additional U.S. Patent Claim Covering Use of Creatine or Creatine Compounds for Skin Preservation
February 22, 2007
Avicena to Present at Empire Financial Group 2007 Annual Conference
February 13, 2007
Avicena Appoints Dr. Uri Sagman to Board of Directors
February 12, 2007
Avicena to Present at BIO CEO & Investor Conference 2007
February 5, 2007
Avicena Completes Dose-Escalation Portion of Chronic Toxicology Study of Parkinson's Disease Drug Candidate PD-02
December 12, 2006
Avicena Advances Clinical Development of HD-02 for Huntington's Disease
December 06, 2006
Avicena Signs Agreement with the National Institute of Neurological Disorders and Stroke for Phase III Trial for Novel Parkinson's Disease Candidate
November 21, 2006
Avicena Group Reports Third Quarter 2006 Results
October 18, 2006
Avicena Announces Completion of Patient Enrollment for the First Stage of ALS-08 Phase II Clinical Trial for ALS
October 13, 2006
Avicena Group to Present at 2006 BIO InvestorForum
September 8, 2006
Avicena To Present At Merriman Curhan Ford & Co.'s Investor Summit 2006
July 06, 2006
Avicena Initiates Study Of Combination Therapies For Amyotrophic Lateral Sclerosis
June 21, 2006
Clinical Study Shows Avicena's Nurigene™ Significantly Increases Skin Firmness and Elasticity
May 23, 2006
Avicena's Nurigene™ Product Line Demonstrates Significant Anti-Aging Properties In Clinical Study
May 09, 2006
Avicena Announces Phase III ALS Trial Results
May 02, 2006
Avicena Initiates Novel Creatine Bioequivalency Study Aimed at Optimizing Therapies
April 26, 2006
Avicena Receives Key Patent Governing Creatine's use in Additional Healthcare Applications
April 06, 2006
Avicena Appoints Michael Sullivan Vice President of Finance and Acting Chief Financial Officer
March 22, 2006
Avicena Compound Receives Orphan Drug Designation for Huntington's Disease
March 20, 2006
Avicena Announces Initiation of Stock Trading
March 14, 2006
Avicena Announces Promising Phase II Results from Parkinson's Disease Trial
January 24, 2006
Avicena's HD-02 Demonstrates Potential In Treatment Of Huntington's Disease
November 17, 2005
Avicena Registration Statement Declared Effective by the SEC
|
